Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04254419 | Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells | recruiting | Phase 1 | 18 | Nationwide Children's HospitalOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT05326243 | Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 49 | Pell Bio-Med Technology Co., Ltd.INDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT06139575 | Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer | recruiting | Phase 1 / Phase 2 | 90 | Bivision Pharmaceuticals, Inc.INDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT06307925 | A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 122 | HC Biopharma Inc.INDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT06925464 | CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas | recruiting | Phase 1 / Phase 2 | 36 | Beijing GoBroad HospitalOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06967038 | Chimeric Antigen Receptor Natural Killer Cell Therapy for High-risk Lymphoma Patients With Primary Sjogren's Syndrome(CAR-NK) | recruiting | Phase 1 / Phase 2 | 6 | Bangdong GongOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06968572 | Phase I Study of HSK41959 in Solid Tumors With MTAP Deletion | recruiting | Phase 1 | 245 | Haisco Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT06634394 | APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML | recruiting | Phase 1 | 39 | Aptevo TherapeuticsINDUSTRY | 1 | May 11, 2025 | clinicaltrials |
| NCT06752746 | A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera | recruiting | Phase 1 | 108 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | May 11, 2025 | clinicaltrials |
| NCT04186585 | Recommended Dose Estimation of BP-C2 | recruiting | Phase 1 | 8 | MeddocOTHER | 1 | May 9, 2025 | clinicaltrials |
| NCT06540443 | Pilot Study of MPB-2043 Enhanced MRI for Nodal Staging in Head and Neck Squamous Cell Carcinomas | recruiting | Phase 1 | 24 | MegaPro Biomedical Co. Ltd.INDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT06961617 | Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma | recruiting | Phase 1 | 10 | Lion TCR Pte. Ltd.INDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT06742411 | XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC | recruiting | Phase 1 / Phase 2 | 57 | West China HospitalOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT06304571 | A Study of HC006 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 76 | HC Biopharma Inc.INDUSTRY | 1 | May 6, 2025 | clinicaltrials |
| NCT05263960 | A Study of CM350 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 248 | Keymed Biosciences Co.LtdINDUSTRY | 1 | May 4, 2025 | clinicaltrials |
| NCT06956716 | Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 1 / Phase 2 | 30 | Zhejiang UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT06650566 | Study of LM-299 in Subjects Advanced Malignant Tumors | recruiting | Phase 1 / Phase 2 | 108 | LaNova Medicines LimitedINDUSTRY | 2 | May 2, 2025 | clinicaltrials |
| NCT04503265 | A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 122 | AtlasMedx, IncorporatedINDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT05908409 | A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies(CASSANDRA) | recruiting | Phase 1 / Phase 2 | 37 | IDP Discovery Pharma S.L.INDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT06954558 | A Single-Arm, Open-Label, Phase I Study of GK01 for Advanced Solid Tumor(GUARDIAN) | recruiting | Phase 1 | 15 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT05827796 | IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 70 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | Apr 30, 2025 | clinicaltrials |
| NCT05863234 | Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia | recruiting | Phase 1 / Phase 2 | 7 | Hiroshima University HospitalOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT05994131 | IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC | recruiting | Phase 1 / Phase 2 | 110 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06944444 | A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors | recruiting | Phase 1 | 154 | Shenyang Sunshine Pharmaceutical Co., LTD.INDUSTRY | 1 | Apr 29, 2025 | clinicaltrials |
| NCT05943067 | CD45RA Depleted DLI After TCRα/β Depleted Haploidentical HCT(CD45RADLIHaplo) | recruiting | Phase 1 / Phase 2 | 60 | University Hospital TuebingenOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06946615 | Exploratory Clinical Study of Claudin18.2-Targeted CAR-DC and CAR-T Therapy in Advanced Colorectal Cancer | recruiting | Phase 1 | 18 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT05535413 | UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases | recruiting | Phase 1 / Phase 2 | 30 | Hunan Cancer HospitalOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06188624 | Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers | recruiting | Phase 1 | 150 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06669975 | A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 85 | AP Biosciences Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06907628 | A Trial of SHR-3792 Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 150 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06944457 | Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of MPD-1 in Patients With Advanced Solid Tumor | recruiting | Phase 1 | 24 | Pharosgen Co.,LtdINDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT03571568 | A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL | recruiting | Phase 1 / Phase 2 | 140 | BioInvent International ABINDUSTRY | 6 | Apr 24, 2025 | clinicaltrials |
| NCT06046495 | A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer | recruiting | Phase 1 | 81 | Avistone Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06297941 | Study of REM-422 in Patients With AML or Higher Risk MDS | recruiting | Phase 1 | 100 | Remix TherapeuticsINDUSTRY | 2 | Apr 23, 2025 | clinicaltrials |
| NCT06702995 | Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 307 | Evopoint Biosciences Inc.INDUSTRY | 1 | Apr 20, 2025 | clinicaltrials |
| NCT05749432 | A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 51 | Ganzhou Hemay Pharmaceutical Co., LtdINDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06118788 | Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 24 | Guangzhou Bio-gene Technology Co., LtdINDUSTRY | 1 | Apr 17, 2025 | clinicaltrials |
| NCT06754930 | A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC | recruiting | Phase 1 / Phase 2 | 400 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 17, 2025 | clinicaltrials |
| NCT04494503 | Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL | recruiting | Phase 1 / Phase 2 | 123 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Apr 16, 2025 | clinicaltrials |
| NCT05473624 | Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 153 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT06462365 | Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) | recruiting | Phase 1 | 36 | Tr1X, Inc.INDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT06927349 | A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1301 in Advanced Solid Tumors. | recruiting | Phase 1 | 70 | Shandong Boan Biotechnology Co., LtdINDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT04997317 | Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide(PROMENADE) | recruiting | Phase 1 / Phase 2 | 18 | University Hospital, Basel, SwitzerlandOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT05423691 | Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs(TREG108) | recruiting | Phase 1 | 24 | Cellenkos, Inc.INDUSTRY | 1 | Apr 13, 2025 | clinicaltrials |
| NCT06094556 | An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 240 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 13, 2025 | clinicaltrials |
| NCT06480110 | Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer | recruiting | Phase 1 / Phase 2 | 30 | Rigshospitalet, DenmarkOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT06926413 | A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC | recruiting | Phase 1 | 20 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 13, 2025 | clinicaltrials |
| NCT04215809 | Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL | recruiting | Phase 1 | 144 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Apr 10, 2025 | clinicaltrials |
| NCT05588648 | Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma | recruiting | Phase 1 / Phase 2 | 48 | MedPacto, Inc.INDUSTRY | 2 | Apr 10, 2025 | clinicaltrials |
| NCT06431243 | A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 132 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Apr 10, 2025 | clinicaltrials |
Data updated 23 days agoSource updated May 13, 2025source: clinicaltrials